Abstract
The synthesis, structure-activity relationships (SAR), and biological results of pyridyl-substituted azaindole based tricyclic inhibitors of IKK2 are described. Compound 4m demonstrated potent in vitro potency, acceptable pharmacokinetic and physicochemical properties, and efficacy when dosed orally in a mouse model of inflammatory bowel disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Acetamides / chemical synthesis
-
Acetamides / chemistry*
-
Acetamides / pharmacology
-
Administration, Oral
-
Animals
-
Drug Discovery*
-
Enzyme Activation / drug effects
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacology
-
Heterocyclic Compounds, 3-Ring / chemical synthesis
-
Heterocyclic Compounds, 3-Ring / chemistry*
-
Heterocyclic Compounds, 3-Ring / pharmacology
-
Humans
-
I-kappa B Kinase / antagonists & inhibitors*
-
Inflammatory Bowel Diseases / drug therapy
-
Inhibitory Concentration 50
-
Mice
-
Molecular Structure
-
Rats
-
Structure-Activity Relationship
Substances
-
2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimiazo(4,5-d)pyrrolo(2,3-b)pyridin-7-yl)pyridin-2-yl)methyl)acetamide
-
Acetamides
-
Enzyme Inhibitors
-
Heterocyclic Compounds, 3-Ring
-
I-kappa B Kinase
-
Ikbkb protein, mouse